Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06864624 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Study acronym: WU-KONG20
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 1 to 3v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.
Trial Details
NCT Number NCT06864624
Lead Sponsor Tang-Du Hospital
Collaborators: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 NSCLC
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov